Full-Life Technologies To Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
Full-Life Technologies To Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
11/29/22, 2:05 AM
Location
Industry
pharmaceutical manufacturing
Full-Life Technologies, a fully integrated global radiotherapeutics company, today announced an agreement to acquire New Jersey-based Focus-X Therapeutics, a company developing targeted radiopharmaceuticals to treat cancer based on proprietary peptide engineering technology. The acquisition expands Full-Life's pipeline, including two compounds nearing clinical trials, provides a second innovative peptide focused discovery platform, and leverages its Radio Technology manufacturing and logistics platforms to advance compounds into clinical development.
Company Info
Location
Shanghai, Shanghai, China
Company info
Full-Life Technologies Limited (“Full-Life”) is a fully integrated global radiopharmaceutical company with operations in Belgium, Germany, and China. We seek to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and scientists with a demonstrated track record in the life sciences, as well as radioisotope research and clinical development.